An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Choi, Hye Duck; Kim, Ji Hae

doi:https://doi.org/10.1155/2023/7362551

Cardiovascular Therapeutics

On this page

Abstract Introduction Methods Results Discussion Conclusions Abbreviations Data Availability Disclosure Conflicts of Interest Authors’ Contributions Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 7362551 | https://doi.org/10.1155/2023/7362551

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Hye Duck Choi¹and Ji Hae Kim¹

Academic Editor: Baohui Xu

Received11 Oct 2022

Revised10 Dec 2022

Accepted17 Dec 2022

Published04 Jan 2023

Abstract

Background. Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. Methods. We assessed the relative risk for all treatment-related adverse events, serious adverse events, diabetes-related adverse events, and neurocognitive and neurologic adverse events with PCSK9 inhibitors compared to controls (placebo or ezetimibe). In addition, we conducted a meta-analysis to quantitatively integrate and estimate the adverse event rates in long-term studies. Results. There were no significant differences between PCSK9 inhibitors and controls in the relative risk analysis. In a subgroup analysis of each PCSK9 inhibitor, alirocumab treatment significantly reduced the risk of serious adverse events compared to control treatment (; 95% confidence interval (CI), 0.896–0.980), but no significant difference was observed with evolocumab treatment (; 95% CI, 0.963–1.054). Moreover, alirocumab treatment afforded a significant reduction in the risk of diabetes-related adverse events compared to control treatment (; 95% CI, 0.845–0.987). The overall incidence (event rate) of long-term adverse events was 75.1% (95% CI, 71.2%–78.7%), and the incidence of serious long-term event rate was 16.2% (95% CI, 11.6%–22.3%). Conclusions. We suggest that alirocumab and evolocumab are generally safe and well tolerated and that their addition to background lipid-lowering therapy is not associated with an increased risk of adverse events or toxicity.

1. Introduction

Alirocumab and evolocumab are fully human monoclonal antibodies against the protein convertase subtilisin kexin type 9 (PCSK9) and modulate the upregulation of recycling and expression of low-density lipoprotein cholesterol (LDL-C) receptors at the cell surface, and increase LDL-C clearance from circulation [1]. Both PCSK9 inhibitors were approved by the Food and Drug Administration in 2015 and are indicated for patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization [2]. In addition, they are used as an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in patients with primary hyperlipidemia.

In randomized controlled trials, alirocumab and evolocumab have been reported to reduce the risk of recurrent cardiovascular disease in patients following an acute coronary event and secondary prevention populations when added to background statin therapy [3, 4]. In terms of safety, PCSK9 inhibitors are well tolerated and favorable. However, injection-related adverse events, such as injection-site reactions and “flu-like” symptoms after injections, may be a limitation in some patients [1]. In addition, long-term follow-up data on the efficacy or safety of PCSK9 inhibitors are insufficient, and some issues regarding their potential impact on neurocognitive- or diabetes-related risk have not been clearly uncovered [5].

A previous meta-analysis including 25 randomized controlled trials found that alirocumab and evolocumab are generally safe. However, it was reported that alirocumab increased the rate of injection-site reactions, while evolocumab reduced the rate of abnormal liver function [6]. In systematic reviews that evaluated concerns related to diabetes mellitus, the PCSK9 inhibitors were not associated with the risk of new-onset diabetes and adverse events of diabetes mellitus [7, 8]. Similarly, there was no increased risk of neurocognitive adverse events [9]. Since then, more clinical studies of both PCSK9 inhibitors have been reported.

This meta-analysis was conducted to update the safety data for PCSK9 inhibitors to assess the relative risk of alirocumab and evolocumab compared with placebo (or ezetimibe) and to quantitatively integrate and estimate the incidence of adverse events in long-term studies.

2. Methods

2.1. Search Strategy and Study Selection

We searched for published articles reporting adverse events associated with alirocumab and evolocumab in MEDLINE (OVID and PubMed), EMBASE, the Cochrane Library, and http://ClinialTrials.gov. The search was completed on October 30, 2021. The following search terms were used: PCSK9 inhibitors, PCSK9 antibody, evolocumab, AMG 145, alirocumab, SAR236553, and REGN727. We reviewed the reference lists of the retrieved articles and searched the relevant reviews to identify additional eligible studies. There were no restrictions on any publication.

Two authors independently reviewed and selected studies for inclusion in the systematic review. The inclusion criteria were as follows: (1) phase 2, 3, or 4 clinical trials; (2) administration of alirocumab or evolocumab; and (3) safety or adverse drug events. Disagreement about the inclusion of an article in the evaluation was resolved through discussion. For a clinical trial described in multiple reports, we extracted data from the most complete account and used the other publications only for clarification.

The study protocol for this meta-analysis was registered in the International Prospective Register for Systematic Reviews (PROSPERO) CRD42022328637.

2.2. Data Extraction and Quality Assessment

Two authors independently reviewed detailed full-text articles. The data were extracted from each study: number and characteristics of participants, treatment administered (dose regimen and periods), and adverse events. The bias risk of the included studies was assessed by two authors using the Cochrane RoB 2 criteria: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in the measurement of the outcome, and bias in the selection of the reported result [10]. Disagreements between the two authors were resolved by consensus after discussion.

2.3. Meta-Analysis and Statistical Analysis

To evaluate treatment safety, we compared the total number of adverse events and serious adverse events reported in participants treated with alirocumab or evolocumab vs. those treated with placebo or ezetimibe. Moreover, we assessed the total number of diabetes-related, neurocognitive, and neurologic adverse events reported in both treatment groups. Studies with a follow-up period of at least 48 weeks were included to estimate the incidence of long-term adverse events.

The test (employing Q statistics) and the calculating values were used to assess heterogeneity among including studies [11]. Based on the results of the heterogeneity test in each analysis, a fixed-effects model or a random-effects model was applied to the analysis [12, 13].

Publication bias was examined using Begg’s method and Egger’s regression test [14, 15]. Also, we performed sensitivity analyses by excluding the contribution of each study to the meta-analysis data in turn.

We performed all statistical analyses using the Comprehensive Meta-analysis Software version 2 (CMA 26526; Biostat, Englewood, NJ, USA). All values were two-sided, and values <0.05 was considered to indicate statistical significance.

3. Results

3.1. Study Characteristics and Risk of Bias Assessments

A total of 1,709 articles were identified in the literature search. The titles and abstracts of 743 articles were reviewed after excluding duplicates. Of these articles, 637 were excluded, and the full texts of 106 articles were assessed for meeting the eligibility criteria. A further 47 articles were excluded, and the data from the remaining 49 articles were finally included in the present meta-analysis (Figure 1). The general characteristics of included studies are shown in Table 1.

Risk of bias assessments for each study, including all domain judgments and support for judgment, are represented in the risk of bias section in Table 1. The risk of bias in outcomes across all studies was similar and predominately of ‘some concerns’ (Supplementary Table S1).

3.2. Meta-Analysis of All Adverse Events and Serious Adverse Events

Forty-seven studies were included to evaluate any treatment-related adverse events. A total of 35,358 participants treated with PCSK9 inhibitors (alirocumab or evolocumab) and 30,710 participants treated with controls (placebo or ezetimibe) were assessed. No significant differences were observed between the two treatments (; 95% confidence interval (CI), 0.992–1.055) (Table 2).

In the analysis of serious adverse events, 35,046 participants treated with PCSK9 inhibitors and 30,522 participants treated with controls from 44 studies were assessed. No significant differences were observed between the two treatments (; 95% CI, 0.944–1.003). In the subgroup analysis of each PCSK9 inhibitor, alirocumab treatment significantly reduced the risk of serious adverse events compared to the control treatment, but no significant difference was observed with evolocumab treatment (alirocumab: ; 95% CI, 0.896–0.980; evolocumab: ; 95% CI, 0.963–1.054) (Figure 2).

3.3. Meta-Analysis of Diabetes-Related Adverse Events

A total of 21 studies with 51,817 participants (27,770 treated with PCSK9 inhibitors and 24,047 treated with controls) were included. No significant difference was showed in the safety assessment of diabetes-related adverse events (; 95% CI, 0.914–1.023). In subgroup analysis of each PCSK9 inhibitor, alirocumab treatment afforded a significant reduction in the risk of diabetes-related adverse events compared to control treatment (; 95% CI, 0.845–0.987) (Figure 3).

3.4. Meta-Analysis of Neurocognitive and Neurologic Adverse Events

Nineteen studies, including 32,916 participants treated with PCSK9 inhibitors and 29,166 participants treated with controls, were assessed. There was no significant difference in the safety assessment of neurocognitive and neurological adverse events between the two treatments (; 95% CI, 0.913–1.163). There were no significant differences in the subgroup analysis of each PCSK9 inhibitor (Figure 4).

3.5. Incidence of Long-Term Adverse Events

A total of 13 studies were assessed for the long-term risk of all and serious adverse events in 20,969 participants treated with PCSK9 inhibitors. The overall incidence (event rate) of long-term adverse events was 75.1% (95% CI, 71.2%–78.7%), and the incidence of long-term serious event rate was 16.2% (95% CI, 11.6%–22.3%) using the random-effects model (Table 2).

Long-term risk of diabetes-related adverse events was assessed in 10 studies including 24,745 participants treated with PCSK9 inhibitors, and the incidence of diabetes-related adverse events was 4.50% (95% CI, 3.10%–6.50%), when applied the random-effects model (Table 2).

The long-term risk of neurocognitive and neurological adverse events was assessed in 12 studies, including 30,571 participants treated with PCSK9 inhibitors. The incidence of neurocognitive and neurologic adverse events was 1.70% (95% CI, 1.10%–2.70%), when applied the random-effects model (Table 2).

3.6. Publication Bias and Sensitivity Analyses

We evaluated the publication bias and the results of Begg’s and Egger’s tests are shown in Table 2. Sensitivity analysis was also performed by recalculating all findings after omitting the data from each study included in the meta-analysis. The results were not significantly altered throughout this process.

4. Discussion

We performed this meta-analysis to update the safety data for PCSK9 inhibitors to evaluate the relative risks of alirocumab and evolocumab compared to controls. In addition, we conducted a meta-analysis to quantitatively integrate and estimate the incidence of adverse events in long-term studies, which is a meaningful approach for the safety evaluation of PCSK9 inhibitors.

Based on the results of meta-analysis, we suggest that adding PCSK9 inhibitors to statins or other lipid-lowering therapies is not associated with an increased risk of adverse events or toxicity. That is, no significant differences were found in any of the comparisons analyzed, including serious adverse events, diabetes-related adverse events, or neurocognitive and neurological adverse events. Interestingly, alirocumab therapy seems to have a lower risk of diabetes and serious adverse events, which is consistent with a previous meta-analysis [7]. These results may be due to the unique characteristics of alirocumab or the effects of background lipid-lowering therapy.

In particular, diabetes mellitus is a cardiovascular risk and a significant adverse event of lipid-lowering therapies such as statins. Therefore, the use of PCSK9 inhibitors that do not increase the risk of diabetes is recommended. However, considering that most patients with dyslipidemia are treated with combination therapy, diabetes-related monitoring should not be excluded.

Previous studies have reported a higher incidence of neurocognitive events in patients receiving PCSK9 inhibitors than in those receiving standard therapy, but other clinical studies or systematic reviews did not show an increase in neurocognitive deficits in patients receiving these inhibitors [16, 17]. In addition, our meta-analysis showed results that were consistent with those described above. It is known that neither cholesterol nor PCSK9 can cross the blood-brain barrier under normal conditions, and alirocumab or evolocumab also cannot cross the blood-brain barrier [18, 19]. Therefore, we suggest that PCSK9 inhibitors do not cause or increase neurocognitive or neurological adverse events. However, cognitive problems in geriatric patients remain an important issue that requires close monitoring.

One meta-analysis reported that long-term treatment with alirocumab or evolocumab reduced LDL-C levels and improved cardiovascular outcomes while showing a similar safety profile to non-PCSK9 inhibitor therapy [20]. We performed the present meta-analysis to estimate the incidence of long-term adverse events. The overall incidence of long-term adverse events in PCSK9 inhibitor therapy is rather high at 75.1%, but it should be evaluated through (possibly indirect) comparison with the incidence of other comparative drugs. The incidence of diabetes-related adverse events, and neurocognitive and neurological adverse events was estimated to be approximately 4.50% and 1.7%, respectively.

In addition, a recent systematic review suggested that no major safety issues associated with PCSK9 inhibitors were observed, which is consistent with our results [21]. They also suggested that the use of PCSK9 inhibitors significantly reduced the risk of MI, ischemic stroke, and coronary revascularization in patients with dyslipidemia or atherosclerotic cardiovascular disease. These results, including our meta-analysis, are the evidences that support the role of PCSK9 inhibitors as treatments for dyslipidemia, and are expected to further increase their clinical use.

Our study had several limitations. First, we performed a meta-analysis based on previously reported articles which were not necessarily complete or accurate and the results may be partially different when applied to individual patients. Second, significant heterogeneity was present in the analyses, and dividing the studies into subgroups or performing a sensitivity analysis failed to identify the sources of heterogeneity. Despite these limitations, this meta-analysis is meaningful in that it provides clinical evidence for better pharmacotherapy in patients with dyslipidemia.

5. Conclusions

There were no significant differences between the PCSK9 inhibitors and controls, including serious adverse events, diabetes-related adverse events, or neurocognitive and neurological adverse events. PCKS9 inhibitors are relatively safe and well tolerated, and their addition to background lipid-lowering therapy is not associated with an increased risk of adverse events or toxicity.

Abbreviations

CI:	Confidence interval
LDL-C:	Low-density lipoprotein cholesterol
PCSK9:	Protein convertase subtilisin kexin type 9
RR:	Risk ratio.

Data Availability

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author upon request.

Disclosure

The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare that there is no conflict of interests.

Authors’ Contributions

Choi HD and Kim JH conceived the study, conducted the search, and collected the data. Choi HD performed the analysis. Choi HD and Kim JH wrote and reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government, Ministry of Science, and ICT (Grant No. 2022R1F1A1074583). A PRISMA2020 checklist for this meta-analysis was provided in Supplementary Table S2.

Supplementary Materials

Supplementary 1. Table S1: Risk of bias.

Supplementary 2. Table S2: PRISMA 2020 checklist.

References

R. S. Rosenson, R. A. Hegele, S. Fazio, and C. P. Cannon, “The evolving future of PCSK9 inhibitors,” Journal of the American College of Cardiology, vol. 72, no. 3, pp. 314–329, 2018.
View at: Publisher Site | Google Scholar
D. M. Lloyd-Jones, P. B. Morris, C. M. Ballantyne et al., “2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways,” Journal of the American College of Cardiology, vol. 70, no. 14, pp. 1785–1822, 2017.
View at: Publisher Site | Google Scholar
G. G. Schwartz, P. G. Steg, M. Szarek et al., “Alirocumab and cardiovascular outcomes after acute coronary syndrome,” The New England Journal of Medicine, vol. 379, no. 22, pp. 2097–2107, 2018.
View at: Publisher Site | Google Scholar
M. S. Sabatine, R. P. Giugliano, A. C. Keech et al., “Evolocumab and clinical outcomes in patients with cardiovascular disease,” The New England Journal of Medicine, vol. 376, no. 18, pp. 1713–1722, 2017.
View at: Publisher Site | Google Scholar
C. E. Kosmas, A. Skavdis, A. Sourlas et al., “Safety and tolerability of PCSK9 inhibitors: current insights,” Clinical Pharmacology: Advances and Applications, vol. 12, pp. 191–202, 2020.
View at: Publisher Site | Google Scholar
X. L. Zhang, Q. Q. Zhu, L. Zhu et al., “Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials,” BMC Medicine, vol. 13, no. 1, p. 123, 2015.
View at: Publisher Site | Google Scholar
W. G. Chen TrQ, C. Li, X. Qin, R. Liu, and M. Zhang, “Safety of Proprotein convertase Subtilisin/Kexin type 9 monoclonal antibodies in regard to diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials,” American Journal of Cardiovascular Drugs, vol. 20, no. 4, pp. 343–353, 2020.
View at: Publisher Site | Google Scholar
L. S. F. de Carvalho, A. M. Campos, and A. C. Sposito, “Proprotein convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years,” Diabetes Care, vol. 41, no. 2, pp. 364–367, 2018.
View at: Publisher Site | Google Scholar
N. S. Bajaj, N. Patel, R. Kalra et al., “Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons,” European Heart Journal - Quality of Care and Clinical Outcomes, vol. 4, no. 2, pp. 132–141, 2018.
View at: Publisher Site | Google Scholar
J. P. T. Higgins, J. Thomas, J. Chandler et al., Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, Chichester (UK), 2nd edition, 2019.
View at: Publisher Site
W. G. Cochran, “The combination of estimates from different experiments,” Biometrics, vol. 10, no. 1, pp. 101–129, 1954.
View at: Publisher Site | Google Scholar
N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” Journal of the National Cancer Institute, vol. 22, no. 4, pp. 719–748, 1959.
View at: Google Scholar
R. DerSimonian and N. Larid, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.
View at: Publisher Site | Google Scholar
C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometircs, vol. 50, no. 4, pp. 1088–1101, 1994.
View at: Publisher Site | Google Scholar
M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” BMJ, vol. 315, no. 7109, pp. 629–634, 1997.
View at: Publisher Site | Google Scholar
M. J. Koren, R. P. Giugliano, F. J. Raal et al., “Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial,” Circulation, vol. 129, no. 2, pp. 234–243, 2014.
View at: Publisher Site | Google Scholar
E. M. Roth and J. M. McKenney, “ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks,” Future Cardiology, vol. 11, no. 1, pp. 27–37, 2015.
View at: Publisher Site | Google Scholar
E. M. O’Connell and F. W. Lohoff, “Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders,” Frontiers in Neuroscience, vol. 14, p. 609, 2020.
View at: Publisher Site | Google Scholar
D. Bandyopadhyay, K. Ashish, A. Hajra, A. Qureshi, and R. K. Ghosh, “Cardiovascular outcomes of PCSK9 inhibitors: with special emphasis on its effect beyond LDL-cholesterol lowering,” Journal of Lipids, vol. 2018, Article ID 3179201, 13 pages, 2018.
View at: Publisher Site | Google Scholar
J. Bai, L. L. Gong, Q. F. Li, and Z. H. Wang, “Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: a meta-analysis of 11 randomized controlled trials,” Journal of Clinical Lipidology, vol. 12, no. 2, pp. 277–91.e3, 2018.
View at: Publisher Site | Google Scholar
P. Guedeney, G. Giustino, S. Sorrentino et al., “Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials,” European Heart Journal, vol. 43, pp. e17–e25, 2019.
View at: Publisher Site | Google Scholar
R. P. Giugliano, N. R. Desai, P. Kohli et al., “Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo- controlled, dose-ranging, phase 2 study,” Lancet, vol. 380, no. 9858, pp. 2007–2017, 2012.
View at: Publisher Site | Google Scholar
M. J. Koren, R. Scott, J. B. Kim et al., “Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo- controlled, phase 2 study,” Lancet, vol. 380, no. 9858, pp. 1995–2006, 2012.
View at: Publisher Site | Google Scholar
F. Raal, R. Scott, R. Somaratne et al., “Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial,” Circulation, vol. 126, no. 20, pp. 2408–2417, 2012.
View at: Publisher Site | Google Scholar
D. Sullivan, A. G. Olsson, R. Scott et al., “Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients,” Journal of the American Medical Association, vol. 308, no. 23, pp. 2497–2506, 2012.
View at: Publisher Site | Google Scholar
D. J. Blom, T. Hala, M. Bolognese et al., “A 52-week placebo-controlled trial of evolocumab in hyperlipidemia,” The New England Journal of Medicine, vol. 370, no. 19, pp. 1809–1819, 2014.
View at: Publisher Site | Google Scholar
A. Hirayama, N. Honarpour, M. Yoshida et al., “Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study,” Circulation Journal, vol. 78, no. 5, pp. 1073–1082, 2014.
View at: Publisher Site | Google Scholar
M. J. Koren, P. Lundqvist, M. Bolognese et al., “Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab,” Journal of the American College of Cardiology, vol. 63, no. 23, pp. 2531–2540, 2014.
View at: Publisher Site | Google Scholar
J. G. Robinson, B. S. Nedergaard, W. J. Rogers et al., “Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with Hypercholesterolemia,” Journal of the American Medical Association, vol. 311, no. 18, pp. 1870–1882, 2014.
View at: Publisher Site | Google Scholar
E. Stroes, D. Colquhoun, D. Sullivan et al., “Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab,” Journal of the American College of Cardiology, vol. 63, no. 23, pp. 2541–2548, 2014.
View at: Publisher Site | Google Scholar
F. J. Raal, N. Honarpour, D. J. Blom et al., “Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo- controlled trial,” Lancet, vol. 385, no. 9965, pp. 341–350, 2015.
View at: Publisher Site | Google Scholar
F. J. Raal, E. A. Stein, R. Dufour et al., “PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo- controlled trial,” Lancet, vol. 385, no. 9965, pp. 331–340, 2015.
View at: Publisher Site | Google Scholar
S. J. Nicholls, R. Puri, T. Anderson et al., “Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial,” Journal of the American Medical Association, vol. 316, no. 22, pp. 2373–2384, 2016.
View at: Publisher Site | Google Scholar
A. Kiyosue, N. Honarpour, C. Kurtz, A. Xue, S. M. Wasserman, and A. Hirayama, “A phase 3 study of Evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk,” The American Journal of Cardiology, vol. 117, no. 1, pp. 40–47, 2016.
View at: Publisher Site | Google Scholar
F. J. Raal, G. K. Hovingh, D. Blom et al., “Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study,” The Lancet Diabetes and Endocrinology, vol. 5, no. 4, pp. 280–290, 2017.
View at: Publisher Site | Google Scholar
L. C. A. Stiekema, E. S. G. Stroes, S. L. Verweij et al., “Persistent arterial wall inflammation in patients with elevated lipoprotein (a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment,” European Heart Journal, vol. 40, no. 33, pp. 2775–2781, 2019.
View at: Publisher Site | Google Scholar
S. Koba, I. Inoue, M. Cyrille et al., “Evolocumab vs. ezetimibe in statin-intolerant hyperlipidemic Japanese patients: phase 3 gauss-4 trial,” Journal of Atherosclerosis and Thrombosis, vol. 27, no. 5, pp. 471–484, 2020.
View at: Publisher Site | Google Scholar
A. J. Lorenzatti, F. G. Eliaschewitz, Y. Chen et al., “Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: primary results of the BERSON clinical trial,” Diabetes, Obesity & Metabolism, vol. 21, no. 6, pp. 1455–1463, 2019.
View at: Publisher Site | Google Scholar
R. S. Rosenson, M. L. Daviglus, Y. Handelsman et al., “Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study,” Diabetologia, vol. 62, no. 6, pp. 948–958, 2019.
View at: Publisher Site | Google Scholar
F. Boccara, P. N. Kumar, B. Caramelli et al., “Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study,” Journal of the American College of Cardiology, vol. 75, no. 20, pp. 2570–2584, 2020.
View at: Publisher Site | Google Scholar
R. D. Santos, A. Ruzza, G. K. Hovingh et al., “Evolocumab in pediatric heterozygous familial hypercholesterolemia,” The New England Journal of Medicine, vol. 383, no. 14, pp. 1317–1327, 2020.
View at: Publisher Site | Google Scholar
J. M. McKenney, M. J. Koren, D. J. Kereiakes, C. Hanotin, A. C. Ferrand, and E. A. Stein, “Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy,” Journal of the American College of Cardiology, vol. 59, no. 25, pp. 2344–2353, 2012.
View at: Publisher Site | Google Scholar
E. M. Roth, J. M. McKenney, C. Hanotin, G. Asset, and E. A. Stein, “Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia,” The New England Journal of Medicine, vol. 367, no. 20, pp. 1891–1900, 2012.
View at: Publisher Site | Google Scholar
E. A. Stein, N. Honarpour, S. M. Wasserman, F. Xu, R. Scott, and F. J. Raal, “Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia,” Circulation, vol. 128, no. 19, pp. 2113–2120, 2013.
View at: Publisher Site | Google Scholar
E. M. Roth, M. R. Taskinen, H. N. Ginsberg et al., “Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial,” International Journal of Cardiology, vol. 176, no. 1, pp. 55–61, 2014.
View at: Publisher Site | Google Scholar
P. M. Moriarty, P. D. Thompson, C. P. Cannon et al., “Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial,” Journal of Clinical Lipidology, vol. 9, no. 6, pp. 758–769, 2015.
View at: Publisher Site | Google Scholar
H. Bays, D. Gaudet, R. Weiss et al., “Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial,” The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 8, pp. 3140–3148, 2015.
View at: Publisher Site | Google Scholar
D. J. Kereiakes, J. G. Robinson, C. P. Cannon et al., “Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study,” American Heart Journal, vol. 169, no. 6, pp. 906–915.e13, 2015.
View at: Publisher Site | Google Scholar
J. J. Kastelein, H. N. Ginsberg, G. Langslet et al., “ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia,” European Heart Journal, vol. 36, no. 43, pp. 2996–3003, 2015.
View at: Publisher Site | Google Scholar
R. Dufour, G. K. Hovingh, J. R. Guyton et al., “Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: results from an open-label extension of the ODYSSEY LONG TERM trial,” Journal of Clinical Lipidology, vol. 13, no. 1, pp. 138–147, 2019.
View at: Publisher Site | Google Scholar
M. Farnier, P. Jones, R. Severance et al., “Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial,” Atherosclerosis, vol. 244, pp. 138–146, 2016.
View at: Publisher Site | Google Scholar
P. M. Moriarty, K. G. Parhofer, S. P. Babirak et al., “Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial,” European Heart Journal, vol. 37, no. 48, pp. 3588–3595, 2016.
View at: Publisher Site | Google Scholar
E. M. Roth, P. M. Moriarty, J. Bergeron et al., “A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I,” Atherosclerosis, vol. 254, pp. 254–262, 2016.
View at: Publisher Site | Google Scholar
E. Stroes, J. R. Guyton, N. Lepor et al., “Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study,” Journal of the American Heart Association, vol. 5, no. 9, article e003421, 2016.
View at: Publisher Site | Google Scholar
T. Teramoto, M. Kobayashi, H. Tasaki et al., “Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY JAPAN randomized controlled trial,” Circulation Journal, vol. 80, no. 9, pp. 1980–1987, 2016.
View at: Publisher Site | Google Scholar
T. Teramoto, M. Kobayashi, K. Uno et al., “Efficacy and safety of Alirocumab in Japanese subjects (phase 1 and 2 studies),” The American Journal of Cardiology, vol. 118, no. 1, pp. 56–63, 2016.
View at: Publisher Site | Google Scholar
C. P. Cannon, B. Cariou, D. Blom et al., “Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial,” European Heart Journal, vol. 36, no. 19, pp. 1186–1194, 2015.
View at: Publisher Site | Google Scholar
H. N. Ginsberg, D. J. Rader, F. J. Raal et al., “Efficacy and safety of Alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher,” Cardiovascular Drugs and Therapy, vol. 30, no. 5, pp. 473–483, 2016.
View at: Publisher Site | Google Scholar
L. A. Leiter, B. Cariou, D. Müller-Wieland et al., “Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial,” Diabetes, Obesity & Metabolism, vol. 19, no. 12, pp. 1781–1792, 2017.
View at: Publisher Site | Google Scholar
K. K. Koh, C. W. Nam, T. H. Chao et al., “A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT),” Journal of Clinical Lipidology, vol. 12, no. 1, pp. 162–72.e6, 2018.
View at: Publisher Site | Google Scholar
K. K. Ray, L. A. Leiter, D. Müller-Wieland et al., “Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM- DYSLIPIDEMIA randomized trial,” Diabetes, Obesity & Metabolism, vol. 20, no. 6, pp. 1479–1489, 2018.
View at: Publisher Site | Google Scholar
J. Ako, K. Hibi, K. Tsujita et al., “Effect of alirocumab on coronary atheroma volume in japanese patients with acute coronary syndrome - the ODYSSEY J-IVUS trial,” Circulation Journal, vol. 83, no. 10, pp. 2025–2033, 2019.
View at: Publisher Site | Google Scholar
T. Teramoto, A. Kiyosue, Y. Ishigaki et al., “Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON,” Journal of Cardiology, vol. 73, no. 3, pp. 218–227, 2019.
View at: Publisher Site | Google Scholar
D. J. Blom, M. Harada-Shiba, P. Rubba et al., “Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial,” Journal of the American College of Cardiology, vol. 76, no. 2, pp. 131–142, 2020.
View at: Publisher Site | Google Scholar
Y. Han, J. Chen, V. Chopra et al., “ODYSSEY EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand,” Journal of Clinical Lipidology, vol. 14, no. 1, pp. 98–108.e8, 2020.
View at: Publisher Site | Google Scholar
M. J. Janik, D. V. Urbach, E. van Nieuwenhuizen et al., “Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study,” Atherosclerosis, vol. 331, pp. 20–27, 2021.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Hye Duck Choi and Ji Hae Kim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1331

Downloads

732

Citations